Medical Doctor Program year 2021 Reported 2019–2021 Source: CMS Open Payments, 2026 publication

Jeffrey Metzger

Internal Medicine Danbury, CT Medical Doctor

NPI 1558328344 CMS profile 25159

100 Reserve Rd Ste A4, Danbury, CT 06810

Open in the dashboard

General payments

$2,822

186 records reported · program years 2019–2021

Research payments

$0

Paid to them · None reported · program years 2019–2021

Ownership & investment interest

$0

None reported

Through program year 2021, Jeffrey Metzger of Danbury, CT is reported in the CMS Open Payments database as having received $2,822 across 186 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 83rd percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2021 General $38 2
2020 General $391 24
2019 General $2,393 160

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jeffrey Metzger
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Jeffrey Metzger were reported at $0. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Jeffrey Metzger Internal Medicine median Middle half National median
2019 $2,393 $159 $48–$570 $163
2020 $391 $119 $33–$402 $114
2021 $38 $135 $37–$521 $132
2022 $0 $141 $42–$496 $149
2023 $0 $149 $45–$519 $160
2024 $0 $154 $47–$537 $164
2025 $0 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2021
  1. Boehringer Ingelheim Pharmaceuticals, Inc. $388 23 payments
  2. Novo Nordisk Inc $271 15 payments
  3. AstraZeneca Pharmaceuticals LP $269 17 payments
  4. GlaxoSmithKline, LLC. $226 13 payments
  5. Pfizer Inc. $220 33 payments
  6. Amarin Pharma Inc. $197 13 payments
  7. Merck Sharp & Dohme Corporation $187 13 payments
  8. E.R. Squibb & Sons, L.L.C. $139 9 payments
  9. AbbVie, Inc. $138 2 payments
  10. Sanofi-Aventis U.S. LLC $115 6 payments
  11. Other $673 42 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2021
  1. Food and Beverage $2,800 182 payments
  2. Education $22 4 payments
Products named General payments · program years 2019–2021
  1. SPIRIVA RESPIMAT $314 18 payments
  2. Ozempic $224 12 payments
  3. TRELEGY ELLIPTA $175 10 payments
  4. Vascepa $175 12 payments
  5. JANUMET $146 9 payments
  6. JANUVIA $146 9 payments
  7. CHANTIX $145 21 payments
  8. JARDIANCE $145 9 payments
  9. ELIQUIS $139 9 payments
  10. STEGLATRO $127 8 payments
  11. Other $2,539 198 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

356

Median for Internal Medicine: 777

Drug cost

$24,848

Median for Internal Medicine: $73,373

Branded share of claims

9%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Tiagabine Hcl Generic 14 $12,093
Jardiance Empagliflozin Brand 14 $9,297
Levothyroxine Sodium Generic 52 $572
Atorvastatin Calcium Generic 47 $565
Irbesartan Generic 17 $476
Rosuvastatin Calcium Generic 42 $417
Metoprolol Succinate Generic 15 $393
Lisinopril Generic 26 $261
Amlodipine Besylate Generic 43 $243
Sertraline Hcl Generic 41 $195

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Records

186 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Connecticut

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2021

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record